Loargys (pegzilarginase) / Immedica 
Welcome,         Profile    Billing    Logout  
 0 Diseases   4 Trials   4 Trials   17 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Loargys (pegzilarginase) / Immedica
NCT03921541 / 2018-004837-34: Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

Completed
3
32
Europe, Canada, US
Pegzilarginase, Co-ArgI-PEG; AEB1102, Placebo
Aeglea Biotherapeutics
Arginase I Deficiency, Hyperargininemia
01/23
01/23
2022-003722-45: A Clinical Trial to check the safety of weekly below the skin dosing of study drug, Pegzilarginase in subjects with Arginase 1Deficiency. 

Not yet recruiting
3
48
Europe
Pegzilarginase, AEB1102, Solution for injection
Aeglea Biotherapeutics, Inc., Aeglea Biotherapeutics, Inc, Aeglea Biotherapeutics, Inc.,
Arginase I deficiencyHyperargininemia, Arginase I deficiencyHyperargininemia, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT05676853 / 2022-003722-45: A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

Terminated
3
3
Canada
Pegzilarginase, Co-ArgI-PEG, AEB1102
Aeglea Biotherapeutics, Aeglea Biotherapeutics, Inc.,
Arginase I Deficiency, Hyperargininemia
04/23
04/23
NCT06582524: Pegzilarginase in Subjects <24 Months Old with Arginase 1 Deficiency

Recruiting
3
3
Europe
Pegzilarginase, Loargys
Immedica Pharma AB
Arginase 1 Deficiency
12/25
12/25
CAEB1102-102A, NCT03378531 / 2018-003163-67: A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency

Completed
2
14
Europe, Canada, US
AEB1102, Co-ArgI-PEG, Pegzilarginase
Aeglea Biotherapeutics
Arginase I Deficiency, Hyperargininemia
12/22
12/22

Download Options